Market Newsdesk

SUGAR LAND, Texas, Nov. 23, 2020 /PRNewswire/ — Noble Holding Corporation plc (OTC-PINK: NEBLQ, the Company) announced today that the United States Bankruptcy Court for the Southern District of Texas has issued an order approving the Company’s Joint Plan of Reorganization (the “Plan”).  The Company is working towards emergence as soon as possible upon receipt of certain regulatory approvals which could be received late this year or early 2021.

The Plan received widespread support from creditors and upon emergence will equitize all outstanding bond debt, which currently totals $3.4 billion, and provide for a new $200 million investment in the form of second lien notes as well as a new $675 million secured credit facility.

Robert W. Eifler, President and Chief Executive Officer of the Company, stated, “We are pleased to have reached this critical milestone and are eager to continue executing on our strategy.  I would like to thank our creditors, customers, vendors, advisors and employees, whose support throughout this process has been critical to reaching a consensual and efficient restructuring while maintaining our industry-leading operations.  We look forward to emerging with a significantly improved balance sheet and remain committed to delivering the operational excellence that our customers have come to expect from Noble.”

About Noble Holding Corporation plc
In November 2020, Noble Corporation plc changed its name to Noble Holding Corporation plc to allow the ultimate parent company that emerges from the Chapter 11 reorganization to use the name “Noble Corporation plc.” Noble is a leading offshore drilling contractor for the oil and gas industry. The Company owns and operates one of the most modern, versatile and technically advanced fleets in the offshore drilling industry. Noble performs, through its subsidiaries, contract drilling services with a fleet of 19 offshore drilling units, consisting of 7 drillships and semisubmersibles and 12 jackups, focused largely on ultra-deepwater and high-specification jackup drilling opportunities in both established and emerging regions worldwide. Noble is a public limited company registered in England and Wales with company number 08354954 and registered office at 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT. Additional information on Noble is available at www.noblecorp.com.

Forward-looking Disclosure Statement
Statements regarding Chapter 11 proceedings, including timing of emergence, stock exchange listing and related timing, as well as any other statements that are not historical facts in this release, are forward-looking statements that involve certain risks, uncertainties and assumptions. These include but are not limited to regulatory and legal approvals, consents and reviews, actions or claims by regulatory authorities, customers and other third parties, operating hazards and delays, risks associated with operations outside of the U.S., legislation and regulations affecting drilling operations, compliance with regulatory requirements, factors affecting the level of activity in the oil and gas industry, supply and demand of drilling rigs, factors affecting the duration of contracts, the actual amount of downtime, violations of anti-corruption laws, hurricanes and other weather conditions, public health threats including the COVID-19 (Coronavirus Disease 2019) pandemic, market conditions, the future price of oil and gas and other factors detailed in the Company’s most recent Form 10-K, Form 10-Q’s and other filings with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated.

View original content:http://www.prnewswire.com/news-releases/noble-holding-corporation-plc-announces-confirmation-of-plan-of-reorganization-301178882.html

SOURCE Noble Corporation

RADNOR, Pa., Nov. 23, 2020 /PRNewswire/ — Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies & applied materials industries, will participate in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on Wednesday, December 2, 2020. Michael Stubblefield, President and CEO at Avantor, will represent Avantor in the segment beginning at approximately 2:40 p.m. Eastern Time. 

A live webcast may be accessed through the investor relations section of Avantor’s website at https://ir.avantorsciences.com/investors/events-and-presentations/ and will be available for replay through December 31, 2020.

About Avantor
Avantor^®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. One of our greatest strengths comes from having a global infrastructure that is strategically located to support the needs of our customers. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. For more information, please visit www.avantorsciences.com.

Media Contact

Allison Hosak

Senior Vice President, Global Communications
Avantor
908-329-7281
[email protected]

Investor Relations Contact

Tommy J. Thomas, CPA
Vice President, Investor Relations
Avantor
781-375-8051
[email protected]

 

View original content:http://www.prnewswire.com/news-releases/avantor-to-participate-at-the-evercore-isi-3rd-annual-healthconx-virtual-conference-301178432.html

SOURCE Avantor and Financial News

COLUMBUS, Ga., Nov. 23, 2020 /PRNewswire/ — Despite pandemic economic hardships, National Retail Federation forecasting shows consumers will spend just under $1,000 this holiday season — with speculations centering on how Americans have extra cash on hand due to spending more time at home because of the pandemic. However, according to the 2020 Aflac Health Care Issues Survey released by Aflac, a leading provider of supplemental insurance and products in the U.S., the expenses health insurance doesn’t cover may make many American families cash in on this so-called “quarantine savings” to pay for out-of-pocket medical costs rather than on holiday gifts for their loved ones.

The second annual national online survey of 1,138 U.S. adults looked at how medical costs over the last two years have affected Americans during the holiday season and year-round, as well as the rate of hospital visits, regrets related to health care coverage decisions and COVID-19’s ramifications.

The ongoing rise in health care costs is hitting American families hard, and the challenges posed by the global health crisis are an aggravating factor. Among families with children under 18 in their household who visited the hospital in the past two years, 70% faced significant out-of-pocket medical expenses beyond a copay or deductible during their most recent hospital visit. Of these, 64% said they spent $500 or more in out-of-pocket costs, up from 58% in 2019, and 45% of families said they spent $1,000 or more in out-of-pocket costs, up from 37% last year.

“As a mother of three and a businesswoman, I have seen firsthand how the pandemic has shaped everything from how and where kids learn to how and where employees work,” said Stephanie Shields, senior vice president of Broker Sales at Aflac. “In a year ripe with change, one constant remains: High medical costs continue disrupting American families, many of whom may be unprepared for the out-of-pocket expenses health insurance doesn’t cover.”

Because of these financial difficulties, many families may find it difficult to fill in their loved ones’ stockings this holiday season. Within the past two years, nearly 3 in 4 (71%) families said they had to make some sort of sacrifice or hard decision during the holiday season because of medical cost concerns, including:

• Fewer presents underneath the tree — More than 1 in 5 said they spent less on holiday gifts or went without giving them altogether (23%), decided against purchasing a gift for a loved one (21%) and reduced their overall holiday spending (21%).
• Risky debt on the rooftop — Nearly one-third (28%) said they relied on a credit card, and 21% borrowed money from a friend or family member.
• Home alone for the holidays — Over 1 in 5 said they canceled events (23%) and put a stop to travel plans to see family or friends (21%).

In addition, over one-third of families (37%) said they made health care coverage decisions they regret within the past two years. The top reasons for this benefits remorse include choosing a plan with limited benefits (41%), choosing too high of a deductible (40%), going to an out-of-network doctor (39%) and not sufficiently researching benefits (31%).

“It’s natural for people to have regrets after making decisions about their medical plan, which can impact their future,” said Shields. “While no one could have foreseen what’s occurred in 2020, it is essential to learn from the past and educate yourself on the role health care benefits like supplemental insurance can play in helping with the expenses health insurance doesn’t cover. Doing so can lead to greater confidence in the coverage you choose and, hopefully, fewer regrets and financial woes, meaning families can focus on getting and staying well.”

COVID-19’s Impact

At the time of the survey, 16% of families said they or a member of their household was diagnosed with or received treatment for COVID-19, making it the third top health condition among eight prevalent conditions presented that families said they faced. But its impression has been staggering: Compared to the 62% of families surveyed who said they have been to a hospital in the past two years for an outpatient procedure, an overnight stay or both, a full 3 in 4 families who faced COVID-19 said they or someone in their household required hospitalization as a result.

The top-two conditions surveyed families said they have encountered are diabetes (35%) and cancer (16%), with heart attack (14%) and stroke (13%) ranking a close fourth and fifth. According to the Centers for Disease Control and Prevention, each of these conditions is a common comorbidity putting the afflicted at a heightened risk of severe illness from COVID-19.

Interestingly, over 3 in 4 (79%) of those who said they or a household member was diagnosed with or received treatment for COVID-19 also said they faced medical expenses beyond a copay or deductible during their most recent hospital visit. Despite the reason or season, these families have had to make hard choices about their health and finances due to medical costs year-round, including relying on a credit card (44%), postponing seeing a medical professional (37%) or taking a family member to see a medical professional (33%), working extra to offset medical expenses (31%) and taking out a loan (30%).

Perhaps not surprising, for those who said they or a household member was diagnosed with or received treatment for COVID-19, 62% admit coverage regrets within the past two years.

Survey findings for all respondents, not just families with children, are also available and held steady across all groups. Learn more about the financial effects of health care issues and how Aflac can help with the expenses health insurance doesn’t cover at Aflac.com/HCI.

Methodology
The 2020 Aflac Health Care Issues Survey is a national online survey of 1,138 U.S. adults fielded in August 2020 by Hill+Knowlton Strategies. To learn more about the survey findings, visit Aflac.com/HCI.

About Aflac Incorporated

Aflac Incorporated (NYSE: AFL) is a Fortune 500 company, helping provide protection to more than 50 million people through its subsidiaries in Japan and the U.S., where it is a leading supplemental insurer by paying cash fast when policyholders get sick or injured. For more than six decades, insurance policies of Aflac Incorporated’s subsidiaries have given policyholders the opportunity to focus on recovery, not financial stress. Aflac Life Insurance Japan is the leading provider of medical and cancer insurance in Japan, where it insures 1 in 4 households. Fortune magazine recognized Aflac as one of the 100 Best Companies to Work for in America for 20 consecutive years. For 14 consecutive years, Aflac has been recognized by Ethisphere as one of the World’s Most Ethical Companies. In 2020, Fortune included Aflac Incorporated on its list of World’s Most Admired Companies for the 19th time, and Bloomberg added Aflac Incorporated to its Gender-Equality Index, which tracks the financial performance of public companies committed to supporting gender equality through policy development, representation and transparency. To learn how to get help with expenses health insurance doesn’t cover, get to know us at Aflac.com.

Aflac | Aflac New York | WWHQ | 1932 Wynnton Road | Columbus, GA 31999.

Media contact: Jon Sullivan, 706.573.7610 or [email protected]

Analyst and investor contact: David A. Young, 706.596.3264 or [email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/rising-medical-costs-in-covid-19-era-threaten-holiday-spending-301178560.html

SOURCE Aflac Incorporated

SAN DIEGO, Nov. 23, 2020 /PRNewswire/ — Johnson Fistel, LLP is investigating potential claims on behalf of Bed Bath & Beyond Inc. (NASDAQ: BBBY) against certain of its officers and directors. 

Recently a class action lawsuit was filed in federal court against the Company on behalf of purchasers of the securities of Bed Bath & Beyond from October 2, 2019 through February 11, 2020 (the “Class Period”).

According to the lawsuit, defendants throughout the Class Period made false and misleading statements and failed to disclose: (1) due to “aggressive disposition of inventory,” the Company lacked sufficient inventory in key categories to support holiday sales; (2) the Company’s internal control over inventory levels and financial reporting were not effective; (3) as a result of the foregoing, the Company was likely to experience reduced sales; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you are a current, long-term shareholder of


Bed Bath & Beyond


, holding shares before



October 2, 2019

, you may have standing to hold Bed Bath & Beyond harmless from the alleged harm caused by the officers and directors of the Company by making them personally responsible. You may also be able to assist in reforming the Company’s corporate governance to prevent future wrongdoing. 

If you are interested in learning more about the investigation, please contact lead analyst Jim Baker ([email protected]) at 619-814-4471. If emailing, please include a phone number. 

Additionally, you can [Click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising.  Past results do not guarantee future outcomes.

Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
[email protected]

[Click here to join this action]

View original content:http://www.prnewswire.com/news-releases/did-you-acquire-bbby-before-october-2-2019–johnson-fistel-investigates-bed-bath–beyond-should-management-be-held-accountable-for-investors-losses-301178871.html

SOURCE Johnson Fistel, LLP

VANCOUVER, BC, Nov. 23, 2020 /CNW/ – The following issues have been halted by IIROC:

Company: Spartan Acquisition Corp.

TSX-Venture Symbol: VDKA.P

All Issues: Yes

Reason: At the Request of the Company Pending News

Halt Time (ET): 8:23 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

VANCOUVER, BC, Nov. 23, 2020 /PRNewswire/ – GoldMining Inc. (the “Company” or “GoldMining“) (TSX: GOLD) (NYSE American: GLDG) is pleased to announce the appointment of Alan Hair and Ken Robertson to the Board of Directors of its subsidiary, Gold Royalty Corp. (“Gold Royalty”).

David Garofalo, Chairman and CEO of Gold Royalty, commented: “We are delighted to welcome these two seasoned mining executives to our board as we execute our strategy and look to grow Gold Royalty as an independent high-quality precious metal royalty and streaming company”.

Mr. Hair is a mineral engineer and senior executive with over 37 years of international experience in the mining and metals industry, including as President and CEO, and formerly COO, of Hudbay Minerals Inc. He holds a Bachelor of Science degree in Mineral Engineering from the University of Leeds and the ICD.D designation from the Institute of Corporate Directors. He is a Director of Bear Creek Mining Corporation and Great Panther Mining Limited.

Mr. Robertson was previously a partner and Global Mining & Metals Group Leader with Ernst & Young LLP (“EY”). During his career at EY in Canada and the United Kingdom, Ken developed extensive experience in initial public offerings, financings, governance and securities regulatory compliance. Mr. Robertson is a certified professional accountant and he serves on the boards of Avcorp Industries Incorporated and Mountain Province Diamonds Inc. He holds a Bachelor of Commerce degree from McMaster University and the ICD.D designation from the Institute of Corporate Directors.

About Gold Royalty Corp.

Gold Royalty Corp., a subsidiary of GoldMining, is a gold-focused royalty company. Gold Royalty’s royalty portfolio is expected to initially comprise of 0.5% to 2.0% net smelter return royalties on 17 gold properties covering 11 of the Company’s projects with additional rights to acquire nine royalty interests from third parties holding royalties on certain of such properties.

About GoldMining Inc.

GoldMining Inc. is a public mineral exploration company focused on the acquisition and development of gold assets in the Americas. Through its disciplined acquisition strategy, GoldMining now controls a diversified portfolio of resource-stage gold and gold-copper projects in Canada, U.S.A., Brazil, Colombia and Peru.

Forward-looking Statements

This document contains certain forward-looking statements that reflect the current views and/or expectations of GoldMining with respect to its business and future events, including expectations and future plans respecting each of GoldMining’s and Gold Royalty’s, business plans and strategies.  Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the markets in which GoldMining and Gold Royalty, operate. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including: the inherent risks involved in the exploration and development of mineral properties, fluctuating metal prices, unanticipated costs and expenses and uncertainties relating to the availability and costs of financing needed in the future. These risks, as well as others, including those set forth in GoldMiningꞌs Annual Information Form for the year ended November 30, 2019, management’s discussion and analysis and other filings with Canadian securities regulators, could cause actual results and events to vary significantly. Accordingly, readers should not place undue reliance on forward-looking statements and information. There can be no assurance that forward-looking information, or the material factors or assumptions used to develop such forward looking information, will prove to be accurate. The Company does not undertake any obligations to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.

View original content:http://www.prnewswire.com/news-releases/goldmining-announces-alan-hair-and-ken-robertson-appointed-to-gold-royalty-corp-board-301178589.html

SOURCE GoldMining Inc.

SAN JOSE, Calif., Nov. 23, 2020 /PRNewswire/ — Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that an IND (Investigational New Drug) application for its prophylactic breast cancer vaccine has been filed with the U.S. Food and Drug Administration.

This vaccine technology was invented by a research team from Cleveland Clinic, led by Dr. Vincent Tuohy, the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research in the Department of Inflammation and Immunity at Cleveland Clinic’s Lerner Research Institute. Anixa has a worldwide, exclusive license to this technology. 

The technology takes advantage of self-proteins that have a function at certain times in life, but then become “retired” and disappear from the body.  One such protein, alpha-lactalbumin, is expressed only in the mammary glands during lactation and then disappears once lactation ceases.  Dr. Tuohy discovered that this protein is abnormally expressed again when a woman contracts breast cancer, especially Triple Negative Breast Cancer (TNBC), the most deadly form of this disease.  Dr. Tuohy postulated that if women could be immunized against this protein after their childbearing years, the immune system could be trained to destroy cancer cells as they arise while ignoring normal cells that no longer express this protein, thus making it difficult for the cancer to gain critical mass.  Early studies to test this theory demonstrated highly significant prevention of breast cancer in animal models.

The technology is being developed at Cleveland Clinic with funding from the U.S. Department of Defense.  The funding is expected to enable completion of two Phase 1 clinical trials. 

“This has the potential to be a paradigm-shifting clinical study,” said Dr. Tuohy.  “If our data demonstrate results similar to the pre-clinical studies, this vaccine could have a significant impact on breast cancer, the most common malignancy in women.  Furthermore, the way we think about controlling breast cancer may completely change.”

“We look forward to moving this novel technology into the clinical stage of development,” stated Dr. Amit Kumar, President and CEO of Anixa Biosciences.  “If the data in humans is comparable to the data in animals, Dr. Tuohy’s ‘retired’ protein hypothesis will usher in a new way to prevent breast cancer, as well as other types of tumors.”

“This initial clinical trial will be with women who have been diagnosed with high-risk early stage TNBC and are receiving standard of care at Cleveland Clinic,” said Dr. G. Thomas Budd, Department of Medical Oncology at the Taussig Cancer Center at Cleveland Clinic, and the Clinical Investigator who will be conducting the trial.  “We look forward to commencing the Phase 1 clinical trial and evaluating these patients.”

About Anixa Biosciences, Inc.
Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease.  Anixa’s therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function.  The company’s vaccine portfolio consists of a technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC).  Anixa continually examines emerging technologies in complementary fields for further development and commercialization.  Additional information is available at www.anixa.com.

Forward-Looking Statements:
 Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are not statements of historical facts, but rather reflect Anixa’s current expectations concerning future events and results.  We generally use the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “will” and similar expressions to identify forward-looking statements.  Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.  These risks, uncertainties and factors include, but are not limited to, the risk that clinical trial data in humans will not be comparable to data obtained in animal studies, including as it relates to our prophylactic breast cancer vaccine, as well as those factors set forth in “Item 1A – Risk Factors” and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.  You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. 

Investor contact:
Mike Catelani
[email protected]
408-708-9808

Media contact:
Sherry Ash
[email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-and-cleveland-clinic-file-ind-application-for-breast-cancer-vaccine-301178420.html

SOURCE Anixa Biosciences, Inc.

HOLMDEL, N.J., Nov. 23, 2020 /PRNewswire/ — Vonage (Nasdaq: VG), a global leader in cloud communications helping businesses accelerate their digital transformation, has been chosen by global appliances manufacturer, Fisher & Paykel, to drive customer service communications for customers in Australia, New Zealand, Singapore, the United Kingdom and the United States.

Fisher & Paykel is using Vonage’s Messages API to provide instant maintenance support notifications via SMS and enhance post-sale services. The Vonage Messages API embedded within Fisher & Paykel’s platform delivers automated and instant SMS confirmations and reminders on all technician appointments, including self-service links for customers to easily cancel or reschedule the appointment. Fisher & Paykel also uses Vonage to send follow up messages for customer feedback once a job is completed to make ongoing service improvements.

“Today’s customers want to be responded to instantly. They want regular updates from businesses and, more importantly, a two-way communications channel that allows them to share their concerns and feedback quickly and easily,” said Fisher & Paykel Appliances EVP Marketing and Customer Experience, Rudi Khoury. “With Vonage APIs we are able to communicate with customers promptly and create a unique experience giving them control at their fingertips. Vonage also helps Fisher & Paykel make the customer journey – from booking a technician and confirming the appointment to evaluating our service – a seamless process and closes any gaps in customer communications.”

Digital customer experiences continue to play a huge role in engaging with and retaining customers. According to EY, prioritizing customers’ digital journeys and creating new ways to serve customers through virtualized services will help brands meet customer expectations post COVID-19.

“Delivering prompt customer service across multiple countries in a consistent manner can be a challenge. Businesses need a fast and efficient way to reach their customers no matter where they are in the world. Vonage APIs allow companies to instantly reach their customers through their preferred channels at reduced costs, enabling businesses to effectively communicate with their customers and create a better customer experience,” said Sunny Rao, Vonage Senior Vice President and General Manager for the Asia Pacific region.

With an ever-growing network of more than one million registered developers, the Vonage Communications Platform makes it easy for businesses to use APIs to disrupt their industries, and enable the type of business continuity, remote work, and remote delivery of services that is so essential in today’s environment. Vonage APIs allow developers to easily enhance and build innovative customer experiences directly into their existing applications and devices. The Vonage Communications Platform offers a full suite of programmable voice, video, messaging, and email services to forward-thinking businesses worldwide.

To find out more about Vonage, visit www.vonage.com

About Vonage

Vonage (Nasdaq: VG), a global cloud communications leader, helps businesses accelerate their digital transformation. Vonage’s Communications Platform is fully programmable and allows for the integration of Video, Voice, Chat, Messaging and Verification into existing products, workflows and systems. Vonage’s fully programmable unified communications and contact center applications are built from the Vonage platform and enable companies to transform how they communicate and operate from the office or anywhere, providing enormous flexibility and ensuring business continuity.

Vonage Holdings Corp. is headquartered in New Jersey, with offices throughout the United States, Europe, Australia and Asia. To follow Vonage on Twitter, please visit twitter.com/vonage. To become a fan on Facebook, go to facebook.com/vonage. To subscribe on YouTube, visit youtube.com/vonage.

About Fisher & Paykel

Fisher & Paykel, New Zealand’s award-winning appliance brand, has been selling products to change the way people live since 1934. Over time the company has grown into a global organization, now operating in 30 countries with over 4,000 employees and manufacturing in Italy, Thailand and Mexico.

Fisher & Paykel’s design heritage is founded on a pioneering spirit and a culture of curiosity that has challenged conventional appliance design to consistently deliver products tailored to human needs. The company is committed to ongoing research and development with a culture of open innovation, which allows people to work collaboratively to find insights and ideas that connect with customers and respect the planet.

Fisher & Paykel believes everybody deserves good design, because good design is all about making life better.  It has built its success on understanding its consumers and designing innovative products such as the award-winning DishDrawer™ Dishwasher – the world’s first dishwasher in a drawer and the class-leading CoolDrawer™ multi-temperature drawer.

A part of the wider Haier Group since 2012, Fisher & Paykel has strengthened its presence as a premium home appliance brand. Fisher & Paykel’s New Zealand Design Centre, based at two locations in Auckland and Dunedin, has been recognized as one of the wider Haier Group’s five global research and development centers of excellence.

www.fisherpaykel.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/vonage-powers-customer-support-communications-and-authentication-solutions-for-global-manufacturer-fisher–paykel-301178251.html

SOURCE Vonage